Startups
The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.
Overview
Employees
11-50
Founded date
2018
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 10, 2023 | Swiss-based LimmaTech Biologics raises €35M to combat emerging antimicrobial resistance | Read this article in: Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical company, announced on Monday, October 9, that it has secured $37M (approximately €35M) in a Series A round of funding. The investment was co-led b... |
| Oct 9, 2023 | First equity funding for LimmaTech Biologics | |
| Jan 11, 2021 | Can we warp-speed antibiotic development? | Now, advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis. They have been working together to address it under wide-ranging federal guidance issued in March 2015, titled the “U.S. Na... |
| Jan 6, 2020 | Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics | Martin Gilligan → Ahead of the potential commercialization of vonoprazan, gastrointestinal disease-focused Phathom Pharmaceuticals has brought on another former Celgene exec. Last month the company welcomed Terri... |
| Jan 21, 2019 | Novo Holdings' antibiotic resistance fund backs 3 biotechs | Novo Holdings’ REPAIR Impact Fund has revealed investments in three antibiotic resistance startups. The investments funneled around $16 million (€14 million) of the fund’s $165 million budget into the startups to support research into antib... |
| Jan 21, 2019 | Novo Holdings' antibiotic resistance fund backs 3 biotechs | Novo Holdings’ REPAIR Impact Fund has revealed investments in three antibiotic resistance startups. The investments funneled around $16 million (€14 million) of the fund’s $165 million budget into the startups to support research into antib... |
| Dec 10, 2018 | What’s holding pharma back from the next antibiotic breakthrough? | In the five years since the alarm sounded about so-called superbugs, the world has continued to grapple with the staggering health and economic impacts of antibiotic resistance and mounting resistance to antibiotics of last resort. In the U... |
| Feb 28, 2018 | Novo Holdings ponies up $165M for superbug venture fund | Novo Holdings is taking aim at drug-resistant superbugs with a $165 million venture fund. The new Repair Impact Fund is on the lookout for startups, early-stage companies and corporate spinouts in Europe and the U.S. that are working on the... |
| Can we warp-speed antibiotic development? | While doctors scramble to understand the viral illness Covid-19, bacteria pose no small threat, especially given increasing antibiotic resistance and prevalence of superbugs. Medical centers rely on antibiotics to treat everything from post... |
Reviews 0
FAQ about REPAIR Impact Fund · Home
When was REPAIR Impact Fund · Home founded?
REPAIR Impact Fund · Home was founded in 2018.
What has the press written about REPAIR Impact Fund · Home?
Parsers VC has collected 10 articles mentioning REPAIR Impact Fund · Home, among them “Swiss-based LimmaTech Biologics raises €35M to combat emerging antimicrobial resistance” (Oct 10, 2023) and “First equity funding for LimmaTech Biologics” (Oct 9, 2023).
Is REPAIR Impact Fund · Home still active?
Yes, REPAIR Impact Fund · Home is active; its latest activity on Parsers VC dates from Feb 2, 2024.